Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | - | - | - | - | - | - | - | - |
| Revenue Growth % | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | - | - | - | - | - | - | - | - |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - |
| Operating Expenses | 143.3K | 2.09M | 263.7K | 131.92K | 330.93K | 280 | 144.93K | 55 |
| OpEx % of Revenue | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 143.3K | 395.62K | 263.7K | 131.92K | 330.93K | 280 | 144.93K | 55 |
| SG&A % of Revenue | - | - | - | - | - | - | - | - |
| Research & Development | - | - | - | - | - | - | - | - |
| R&D % of Revenue | - | - | - | - | - | - | - | - |
| Other Operating Expenses | - | - | - | - | - | - | - | - |
| Operating Income | -143.3K | -2.09M | -263.7K | -131.92K | -330.93K | -279 | -144.93K | -55 |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 56.7% | -748812.54% | -81.95% | -240054.01% | - | - | - | - |
| EBITDA | -143.3K | -2.09M | -263.7K | -131.92K | -330.93K | 1 | -144.93K | 0 |
| EBITDA Margin % | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 56.7% | -99999900% | -81.95% | - | - | - | - | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 0 | 280 | 0 | 55 |
| EBIT | -143.3K | -2.09M | -263.7K | -131.92K | -330.93K | -279 | -144.93K | -55 |
| Net Interest Income | 2.11M | 2.3M | 2.45M | 2.42M | 1.59M | 0 | 0 | 0 |
| Interest Income | 2.11M | 2.3M | 2.45M | 2.42M | 1.59M | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | - | - | - | - | - | - | - | - |
| Pretax Income | 1.97M | 212.96K | 2.18M | 2.29M | 1.25M | -279 | -144.93K | -55 |
| Pretax Margin % | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | 1.97M | 212.96K | 2.18M | 2.29M | 1.25M | -279 | -144.93K | -55 |
| Net Margin % | - | - | - | - | - | - | - | - |
| Net Income Growth % | 57.07% | 76429.03% | 1607.34% | 4166379.51% | - | - | - | - |
| Net Income (Continuing) | 1.97M | 212.96K | 2.18M | 2.29M | 1.25M | -279 | -144.93K | -55 |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.06 | 0.01 | 0.07 | 0.07 | 49.18 | -0.03 | -0.01 | -0.01 |
| EPS Growth % | -99.88% | 119.27% | - | - | - | - | - | - |
| EPS (Basic) | 0.06 | 0.01 | 0.07 | 0.07 | 130.51 | -0.03 | -0.01 | -0.01 |
| Diluted Shares Outstanding | 23M | 21.01M | 23M | 33.52M | 25.51M | 8.57M | 8.57M | 8.57M |
| Basic Shares Outstanding | 23M | 21.01M | 23M | 33.52M | 9.61M | 8.57M | 5.49M | 5.49M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |